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Summary
Background:  Patients  with  chronic  kidney  disease  have  a  poor  response  to  hepatitis  B  vac-
cine due  to  the  immunodeficiency  conferred  from  chronic  uremia.  A  recombinant  HB  vaccine
containing  an  improved  adjuvant  system  AS04  (HBV-AS04)  has  been  manufactured  but  scarce
evidence exists  on  HBV-AS04  use  among  patients  with  CKD.
Aim: To  assess  efficacy  and  safety  of  an  adjuvanted  recombinant  vaccine  (HBV-AS04)  in  a  large
cohort of  CKD  patients  at  pre-dialysis  stage  (with  susceptibility  to  HBV  infection).
Methods:  Patients  were  prospectively  enrolled  to  receive  four  20-mcg  doses  of  HBV-AS04  by
intramuscular  route  (deltoid  muscle)  at  months  1,  2,  3,  and  4.  Anti-HBs  surface  antibody
concentrations  were  tested  at  intervals  of  1,  2,  3,  4,  and  12  months.  Multivariate  analyses
were performed  to  assess  the  parameters,  which  predicted  immunologic  response  to  HBV-AS04
vaccine.
Results: One  hundred  and  seven  patients  were  included  and  102  completed  the  study.  At  com-
pletion of  vaccine  schedule,  the  frequency  of  responders  (anti-HBs  titers  ≥  10  mIU/mL)  was  95%
(97/102) (mean  anti-HBs  antibody  titers,  688.9  ±  385  mIU/mL),  according  to  per-protocol  anal-
ysis. Serum  haemoglobin  levels  were  greater  in  responder  than  non-  or  low-responder  patients
to HBV-AS04  (P  =  0.04)  and  this  was  confirmed  by  multivariate  analysis.  The  seroprotection
rate at  month  50  was  88%  (30/34)  with  lower  anti-HBs  antibody  titers  (218.5  ±  269.6  mIU/mL,
P =  0.001).  No  major  side  effects  were  observed.
Conclusions:  Our  prospective  study  performed  in  a  real-world  setting  showed  a  high  immuno-
genicity  and  safety  of  HBV-AS04  vaccine  in  patients  with  CKD  not  yet  on  maintenance  dialysis.
Studies provided  with  longer  follow-ups  are  under  way  to  assess  the  durability  of  seroprotectionPlease  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
in responders.
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bbreviations
Es  adverse  events
APD  continuous  ambulatory  peritoneal  dialysis
DC  centers  for  disease  control  and  prevention
I  confidence  intervals
KD  chronic  kidney  disease
KD  EPI  Chronic  Kidney  Disease  Epidemiology  Collaboration
GFR  estimated  glomerular  filtration  rate
SRD  end-stage  renal  disease
I  gastrointestinal
BV  hepatitis  B  virus
CV  hepatitis  C  virus
IV  human  immunodeficiency  virus
D  haemodialysis
FN  interferon
D  peritoneal  dialysis
T  renal  transplant
TROBE  Strengthening  the  Reporting  of  Observational  stud-
ies  in  Epidemiology
ntroduction
iral  hepatitis  B is  a  major  health  challenge  worldwide  and  it
as  been  recently  estimated  that  around  257  million  people
re  living  with  hepatitis  B  virus  infection  (defined  as  hepati-
is  B  surface  antigen  positive).  Hepatitis  B  virus  is  a  double
NA  stranded  virus  leading  to  chronic  hepatitis,  cirrhosis,
epatocellular  carcinoma  and  liver  failure.  Patients  on  dial-
sis  have  high  risk  for  HBV  infection  due  to  skin  breaching,
xposure  to  blood  products,  and  sharing  of  dialysis  machines
nd  ancillary  instrumentation  within  dialysis  rooms  [1]. The
mmune  deficiency  conferred  from  chronic  uremia  is  another
actor,  which  supports  the  transmission  of  HBV  between
atients  on  dialysis.
The  incidence  of  HBV  in  the  dialysis  population  of  the
eveloped  world  has  been  consistently  reduced  due  to  the
creening  of  blood  derived  products  and  the  implementation
f  several  infection  control  procedures  including  universal
recautions,  separate  rooms  and  machines  for  HBsAg  pos-
tive  patients  [2,3].  However,  transmission  of  hepatitis  B
irus  between  patients  on  dialysis  continues  to  occur  in  both
eveloped  [4]  and  developing  [5,6]  countries.
Hepatitis  B  virus  vaccination  is  another  means  of  prevent-
ng  the  spread  of  HBV  in  dialysis  units  and  a  recombinant
BV  vaccine  has  been  made  available  since  the  early  eight-
es.  It  is  well  known,  however,  that  CKD  patients  have  a
oor  immunologic  response  to  HBV  vaccine  compared  to
hose  with  intact  kidneys  [2,3].  The  immunization  rate  is
educed,  and  responder  patients  show  lower  anti-HBs  titers,
hich  fall  logarithmically  after  completion  of  the  vaccina-
ion  schedule.  Numerous  approaches  have  been  adopted
o  improve  the  immunogenicity  of  recombinant  HBV  vac-
ine  in  patients  with  CKD  including  reinforced  HB  vaccine
chedule  [7],  concomitant  use  of  immuno-modulatory  agents
8,9],  vaccination  by  ID  route  [10],  and  administrationPlease  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
f  vaccine  at  pre-dialysis  stage  [11],  among  others.  A
ecombinant  HB  vaccine  containing  an  improved  adjuvant
ystem  (AS04)  has  been  introduced  in  the  market  specifi-
ally  for  patients  with  CKD  [12—17];  it  contains  as  active
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ubstance  20  mcg  recombinant  hepatitis  B surface  antigen
hich  is  adjuvanted  by  AS04C  (containing  3-0-desacyl-
′-monophosphoryl  lipid  A,  MPL),  adsorbed  on  aluminium
hosphate  and  produced  in  Saccharomyces  cerevisiae  by
ecombinant  DNA  technology.  MPL  is  a  powerful  stimu-
ant  of  the  immune  system  and  acts  through  binding  on
he  Toll-like  receptor  4  on  antigen-presenting  cells.  MPL-
timulated  antigen-presenting  cells  express  increased  levels
f  co-stimulatory  molecules  (including  CD86  molecules)  and
ytokines  inducing  strong  humoral  and  cellular  responses.
There  is  limited  information  in  the  medical  literature  on
BV-AS04  vaccine  in  the  CKD  population  [12—17].  We  have
ndertaken  a  prospective,  real-world  study  was  to  assess
mmunogenicity  and  safety  of  HBV-AS04  in  a  large  cohort  of
KD  patients  not  yet  requiring  dialysis  and  who  are  suscep-
ible  to  HBV  infection.
atients and methods
etting  and  study  subjects
his  was  a  prospective,  cohort  study  in  outpatients  on  regu-
ar  follow-up  at  a  metropolitan  hospital  (Milano  city).  There
as  a  program-wide  screening  for  hepatitis  B  virus  infection
usceptibility  and  immunization  since  early  nineties  at  the
nit.  Hepatitis  B  virus  susceptible  patients  with  CKD  were
iven  an  opportunity  to  participating  in  the  study.
Inclusion  criteria  were  receiving  periodic  follow-up  at
 inner  city  nephrology  center,  18  years  or  older,  serum
BsAg/anti-HBs  negative  at  baseline,  and  able  and  will-
ng  informed  consent.  Exclusion  criteria  were  treatment
ith  intravenous  immune  globulin  within  the  last  6  months,
revious  allergic  reactions  including  hypersensitivity  to
omponents  of  vaccine,  contraindication  to  intramuscular
njections,  elevated  liver  enzymes,  serious  systemic  illness,
nd  concomitant  immunosuppressive  therapy.  Patients  with
revious  administration  of  a  vaccine  containing  monophos-
horyl  lipid  A  were  excluded.
The  study  was  considered  exempt  by  the  institutional
eview  board  at  Maggiore  Hospital  and  IRCCS  Foundation,
ilano,  Italy.  It  was  conducted  in  accordance  with  the  ethi-
al  principles  reported  in  the  1996  version  of  the  Declaration
f  Helsinki  and  Good  Clinical  Practice  guidelines.  All  partici-
ants  gave  informed  and  written  consent  before  they  were
nrolled.  The  study  was  reported  according  to  the  STROBE
nitiative  [18]; the  checklist  of  22  items  that  it  is  considered
ssential  for  good  reporting  of  cohort  observational  studies
an  be  found  in  the  Additional  file  n.1.
tudy  design
atients  were  given  four  doses  of  recombinant  vaccine
ormulated  with  an  improved  adjuvant  system  (HBV-AS04,
endrix)  and  manufactured  by  GlaxoSmithKline  Biologicals.
BV-AS04  vaccine  was  administered  as  a  0.5  mL  intramus-
ular  injection  (deltoid  muscle)  according  to  a  0-,  1-,  2-,tion  with  Fendrix  is  effective  and  safe  in  pre-dialysis  CKD
.org/10.1016/j.clinre.2019.06.010
-month  schedule.  In  the  case  of  patients  who  had  been
quipped  with  arteriovenous  dialysis  fistula,  HB  vaccine  was
dministered  to  the  contralateral  arm.  One  dose  of  HBV-
S04  contained  20  mcg  of  recombinant  HBsAg,  50  mcg  of
 IN PRESS+Model
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Table  1  Baseline  characteristics  of  study  patients.
Patients,  n (%)
Gender
Males  74  72.5
Age, years
Mean  (SD)  66.26  ±  14
Ethnicity
Caucasians  94  92.2
Underlying  nephropathy
Polycystic  kidneys  9
Diabetic  nephropathy  11
Glomerulonephritis  19
Nephrosclerosis  25
Unknown  cause  20
Others  18
CKD  stage
CKD  stage  1  0
CKD  stage  2  1
CKD  stage  3  12
CKD  stage  4  52
CKD  stage  5  37
Experienced  patients,  n  3  2.9
Serum creatinine,  mg/dL
Mean  (SD)  3.4  ±  1.23
Azotemia,  mg/dL
Mean  (SD)  107.7  ±  32.3
eGFR,  mL/min/1.73  m2
Mean  (SD)  19.6  ±  9.9
Diabetes  mellitus,  n  32  31.3
Arterial  hypertension,  n  86  84.1
Anti-HCV  positive  patients,  n  2  1.9
Anti-HBc  positive  patients,  n 4  3.9
Haemoglobin,  g/dL
Mean  (SD) 12.05  ±  1.4
Transferrin,  mg/dL
Mean  (SD) 229  ±  41.03
Parathyroid  hormone,  pg/mL
Mean  (SD) 108.0  ±  64.8
25 (OH)  vitamin  D,  ng/mL
Mean  (SD)  23.8  ±  13
a
a
H
H
w
1
R
P
WARTICLECLINRE-1293; No. of Pages 8
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MPL  (3-0-desacyl-4′-monophosphoryl  lipid  A)  and  0.5  mcg  of
aluminium  salt.
The  primary  outcome  of  interest  in  this  study  was  the
seroprotection  rate  in  the  According  to  Protocol  (ATP)
cohort,  as  a  measure  of  efficacy.  The  ATP  cohort  included
all  patients  who  had  complied  with  primary  vaccination  pro-
tocol.  The  secondary  end-point  was  the  frequency  of  side
effects  associated  with  vaccine  administration.
Serum  studies
Upon  entry  into  the  study,  a  baseline  serum  sample  was
obtained.  Samples  for  anti-HBs  antibodies  were  taken  from
all  study  patients  at  intervals  of  1,  2,  3,  4,  and  12  months.
HBV,  HCV,  and  HIV  markers  were  tested  in  all  patients
at  baseline.  Hepatitis  B  surface  antigen  (HBsAg),  antibod-
ies  to  hepatitis  B  surface  antigen  (HBsAb)  and  hepatitis
core  antigen  (HBcAb)  were  measured  in  plasma  samples  by
enzyme  immunoassays  (Abbott  Laboratories,  USA).  Serum
aminotransferase  levels  were  tested  with  spectrophotomet-
ric  methods.  Screening  for  antibody  to  hepatitis  C  virus  was
performed  by  a  third  generation  ELISA  test.  Antibodies  to
the  human  immunodeficiency  virus  were  measured  by  com-
mercially  test  kits  (Abbott  Diagnostics).
A  large  number  of  demographic,  clinical  and  biochemi-
cal  parameters  were  collected  at  baseline  for  each  patient.
Serum  creatinine  was  measured  at  the  beginning  of  the  study
and  used  to  calculate  the  baseline  estimated  GFR  through
the  CKD  EPI  equation.  Study  subjects  were  classified  into  5
groups  (CKD  stage  1—5)  according  to  the  baseline  eGFR  [19].
Safety  and  reactogenicity
The  patients  were  observed  closely  for  at  least  15  minutes
after  each  vaccine  dose.  The  safety  and  reactogenicity  were
evaluated  by  the  patients  recording  solicited  local  (pain,
redness,  swelling)  and  general  (fatigue,  fever,  headache,
and  GI  symptoms)  AEs.  All  local  symptoms  were  consid-
ered  as  related  to  vaccination.  Unsolicited  adverse  events
occurring  within  30  days  after  each  vaccination  regardless
of  attribution  were  also  recorded  as  well  as  any  serious  AE
that  occurred  during  the  whole  study  period  up  to  30  days
after  the  last  vaccination.
Statistical  analysis
Descriptive  analyses  are  expressed  in  terms  of
mean  ±  standard  deviation  for  continuous  variables  and
percentages  for  categorical  variables.  Skewed  variables
were  log  transformed.  We  performed  multivariate  anal-
ysis  by  nominal  logistic  regression  model:  demographic,
clinical  and  biochemical  characteristics  were  adopted  as
independent  variables,  and  anti-HBs  titers  were  assumed  a
dependent  parameter.  Statistical  analysis  was  carried  out
using  the  program  JPM  (SAS  Institute,  USA,  1996).Please  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
Definitions
Successful  vaccine  response  (seroprotection)  was  defined
as  anti-HBs  concentration  ≥  10  IU/L.  Seroconversion  was  an
p
F
p
weGFR: estimated glomerular filtration rate; HCV: hepatitis C
virus; HBc: hepatitis core.
nti-HBs  value  of  1  mIU/mL  or  more.  We  defined  responder
nd  non-responder  patients  according  to  level  of  anti-
Bs  one  month  after  the  final  injection  (non-responders,
BsAb  <  10  IU/L).  Low-responders  were  those  responders
ho  had  detectable  anti-HBs  antibody  ranging  between
0—100  IU/L  one  month  after  the  end  of  vaccine  course.
esults
atient  characteristics
e  originally  enrolled  107  patients,  102  of  them  com-tion  with  Fendrix  is  effective  and  safe  in  pre-dialysis  CKD
.org/10.1016/j.clinre.2019.06.010
leted  the  study,  for  which  per-protocol  analysis  was  done.
ive  patients  did  not  complete  the  vaccine  course  —  three
atients  were  lost  to  follow-up,  and  two  patients  died  or
ithdrew  from  the  study  on  a  voluntary  basis,  respectively.
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sFigure  1  Persistence  of  anti-hepati
The  demographic,  clinical  and  biochemical  parameters  of
he  patients  at  baseline  are  reported  in  Table  1.  The  major-
ty  of  patients  had  Caucasian  origin,  none  had  detectable
uman  immunodeficiency  virus  antibodies  or  admitted  cur-
ent  or  previous  intravenous  drug  use.  The  majority  of
atients  had  advanced  CKD,  as  reported  in  Table  1.
mmunogenicity  of  vaccine
fter  the  first  vaccine  dose,  the  seroprotection  rate  was  12%
3/25)  (Fig.  1).  The  seroprotection  rate  after  the  second  and
hird  dose  was  58%  (30/52)  and  89%  (65/73),  respectively.
he  frequency  of  responders  (anti-HBs  titers  ≥  10  mIU/mL)
ne  month  after  completing  vaccine  course  was  95%
97/102).  The  sero-response  rate  over  follow-up  was  82%
40/49)  and  88%  (30/34)  at  month  12  and  50,  respectively
Fig.  1).
According  to  univariate  analysis  (Table  2),  there  was
o  difference  between  responders  (HBsAb  >  100  IU/L)  and
on-  (n  =  5)  or  low-  (n  =  8)  responders  with  regard  to  vari-
us  demographic,  clinical,  and  biochemical  characteristics.
aemoglobin  and  serum  transferrin  were  greater  among
esponder  patients  (HBsAb  >  100  IU/L)  and  this  was  con-
rmed  by  multivariate  analysis  (Table  3).
After  the  end  of  the  vaccination  cycle,  29  and  9  patients
nitiated  long-term  haemodialysis  and  peritoneal  dialysis,
espectively.  Four  patients  died  and  7  underwent  kidney
ransplant  from  deceased  donor.  Nineteen  patients  were  lost
o  follow-up  and  34  are  still  in  pre-dialysis  CKD  stage  and  in
harge  at  the  nephrology  division.  Nine  patients  are  in  the
ctive  list  for  renal  transplant.Please  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
There  was  significant  difference  with  regard  to  the  mean
iters  at  1,  2,  3,  4,  12  and  50  months  —  anti-HBs  antibody
evels  at  month  50  were  lower  than  that  observed  at  month
2  or  4  (P  =  0.016  and  P  =  0.009),  respectively  (Fig.  2).
(
i
[
F(HBs)  antibody  seroprotection  rates.
afety  of  vaccine
able  4  reports  that  many  patients  (51/102  =  50%)  expe-
ienced  AEs.  The  great  majority  of  the  side  effects
ere  injection-site  AEs;  the  most  common  being  pain
42/102  =  41%).  The  most  common  vaccine-related  systemic
Es  were  headache  and  asthenia  (13/102  =  13%).  Two  deaths
ere  reported  and  none  was  considered  to  be  linked  with  the
dministration  of  HBV-AS04  vaccine  by  the  investigators.
iscussion
he  evidence  in  the  literature  regarding  the  use  of  recombi-
ant  adjuvanted  (HBV-AS04)  vaccines  in  patients  with  CKD  is
xtremely  limited.  In  this  prospective,  cohort  study  aimed
o  assess  immunogenicity  and  safety  of  HBV-AS04  in  a  large
roup  of  CKD  patients  not  yet  requiring  dialysis  we  found  a
igh  immunization  rate  (97/102  =  95%);  of  note,  this  study
oncerns  a  real-life  practice.  As  listed  above,  the  study
roup  presented  several  co-morbidities  at  baseline  (such  as
rterial  hypertension,  diabetes  mellitus,  and  others),  which
re  typical  of  CKD  populations.  The  most  important  paper  on
his  issue  has  been  carried  out  by  Tong  et  al.  [12]  who  con-
ucted  an  open,  randomized  clinical  trial.  It  is  well  known
hat  an  important  shortcoming  of  the  RCTs  is  their  exter-
al  validity  as  they  address  selected  populations  which  are
losely  monitored  over  time.  In  addition,  the  work  by  Tong
t  al.  regarded  mostly  patients  on  long-term  dialysis.
The  data  in  the  medical  literature  regarding  efficacy  and
afety  of  HBV-AS04  are  scarce  and  preliminary  in  naturetion  with  Fendrix  is  effective  and  safe  in  pre-dialysis  CKD
.org/10.1016/j.clinre.2019.06.010
Table  5).  Evidence  exists  in  some  patient  groups  includ-
ng  HIV-positive  patients  [20],  renal  transplant  recipients
17]  and  non-responder  patients  with  intact  kidneys  [21].
endrixTM has  always  shown  a  high  level  of  immunogenicity.
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Table  2  Baseline  characteristics  of  responder  and  non-responder  patients:  univariate  analysis.
Responders  (n  =  89) Non-  or  low-responders  (n  =  13)  P
Gender,  males  65  (73%)  9  (69%)  NS
Age, years  66.01  ±  14.4  68.17  ±  13.2  NS
Ethnicity, Caucasians 81  (91%) 13  (100%) NS
Experienced  patients,  n  3  (3.3%)  0  NS
Serum creatinine,  mg/dL  3.4  ±  1.2  3.5  ±  0.7  NS
Underlying nephropathy  NS
Polycystic kidneys  8  1
Diabetic  nephropathy  9  2
Glomerulonephritis  18  1
Nephrosclerosis  24  1
Unknown  cause 15  5
Others  15  3
CKD stage  NS
CKD stage  1  0  0
CKD stage  2  1  0
CKD stage  3  11  1
CKD stage  4  45  7
CKD stage  5  31  6
Azotemia,  mg/dL  107.1  ±  34  111.7  ±  17.43  NS
eGFR, mL/min/1.73  m2 20.1  ±  10.3  16.2  ±  6.2  NS
Diabetes mellitus,  n  26  (29.2%)  6  (46%)  NS
Arterial hypertension,  n  75  (84.3%)  11  (85%)  NS
Anti-HCV positive  patients,  n  2  (2.2%)  0  NS
Anti-HBc positive  patients,  n  4  (4.5%)  0  NS
Haemoglobin,  g/dL  12  ±  1.47  11.6  ±  1.38  004
Transferrin,  mg/dL  226.2  ±  39.3  247.9  ±  48.5  0.02
Parathyroid  hormone,  pg/mL  105.6  ±  66.7  135.8  ±  66.4  NS
25 (OH)  vitamin  D,  ng/mL  23.1  ±  11.8  28.3  ±  18.9  NS
eGFR: estimated glomerular filtration rate; NS: non significant.
Table  3  Multivariate  analysis:  parameter  estimates  and  effect  test.
Effect  test  NParm  DF  Wald  Chi2 P
Gender  (M/F)  1  1  0.0155  0.90
Age, years  1  1  0.0488  0.82
Creatinine, mg/dL  1  1  0.0254  0.87
Azotemia, mg/dL  1  1  0.0048  0.94
eGFR, mL/min/1.73  m2 1  1  0.0821  0.78
PTH (pg/mL)  1  1  0.023  0.87
25(OH) vit.  D  1  1  0.182  0.67
Diabetes (y/n)  1  1  0.0014  0.96
Haemoglobin,  g/dL 1  1  2.872  0.041
Hypertension  (y/n)  1  1  0.359  0.545
Transferrin,  mg/dL 1  1  5.1967  0.02
Albumin, g/dL 1  1  2.4278  0.07
: yes;
p
oM: male; F: female; eGFR: estimated glomerular filtration rate; y
On  the  other  hand,  further  vaccines  are  being  produced  and
offer  promising  results  [22].Please  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
A  major  result  of  the  current  study  was  the  assessment  of
predictive  factors,  which  could  play  impact  on  the  immune
response  to  HBV-AS04.  Greater  HB  levels  were  an  indepen-
dent  predictor  of  immune  response  to  HBV-AS04  in  our  CKD
p
p
o
a n: no.
opulation.  This  is  in  keeping  with  that  observed  in  patients
n  maintenance  dialysis  [23]. In  contrast  to  what  reported  intion  with  Fendrix  is  effective  and  safe  in  pre-dialysis  CKD
.org/10.1016/j.clinre.2019.06.010
rior  studies  [7,24,25], we  observed  no  link  between  sero-
rotection  rate  and  predictive  factors  such  as  CKD  stage,  age
r  nutritional  status;  this  is  likely  due  to  the  clinical  char-
cteristics  of  the  patient  group.  Finally,  we  cannot  exclude
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Figure  2  Mean  anti-hepatitis  B  (HBs)  antibody  titers  (*mIU
Table  4  Adverse  experience  summary  (days  1  to  30  follow-
ing any  vaccination  visit).
Patients,  n
(n  =  102)
Patients  with  one  or  more  AE  51  (50%)
Patients  with  injection-site  AEs  45  (44.2%)
Erythema  1
Pain  42
Swelling  2
Patients  with  systemic  AEs  13  (12.7%)
Headache  4
Fever  0
Asthenia  9
Gastrointestinal  symptoms  0
Patients  with  serious  AEs  0
Serious  vaccine-related  AEs  0
Patients  who  died  2
Patients  who  discontinued  vaccine  due  to
AEs
0
Maximum  temperature
(Days  1—5  post-vaccine  dose)
> 37.5  0
> 40  0
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standard  schedule  (1,  2,  3  and  6  months)  recommended  byAEs: adverse events.
esidual  confounding  as  the  role  of  additional  factors  includ-
ng  body  mass  index,  smoking,  quality  of  life,  inflammatory
tatus  on  the  immune  response  after  HBV-AS04  was  not
ppropriately  addressed.  An  additional  shortcoming  of  this
tudy  was  that  the  assessment  of  the  decay  rate  of  anti-HBs
iters  following  initial  vaccination  with  HBV-AS04  was  donePlease  cite  this  article  in  press  as:  Fabrizi  F,  et  al.  HBV  vaccina
population.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi
ver  a  long  follow-up  in  a  minority  of  patients  only  (n  =  34).
ndeed,  a  high  number  of  patients  were  lost  to  follow-up.
t  has  already  suggested  that  the  protection  against  HBV  in
t
u
m/mL)  at  the  end  of  vaccine  course  and  over  follow-up.
atients  with  immune  compromise  does  not  rely  on  immune
emory  (in  the  form  of  memory  T  and  B  lymphocytes)  but
n  circulating  anti-HBs  antibody  [26].
The  achievement  of  protective  anti-HBs  titers  can  pro-
ide  numerous  benefits  to  CKD  patients;  first,  evidence
ccumulated  in  the  last  decade  suggests  an  independent  role
f  chronic  HBsAg  carriage  in  increasing  the  incidence  and  the
rogression  of  CKD  in  the  adult  general  population.  The  pres-
nce  of  sublinical  atheromatosis  induced  by  HBV  at  kidney
evel  (atheromatous  plaques  in  the  renal  arteries  and  arte-
ioles)  has  been  mentioned,  irrespective  of  the  glomerular
anifestations  induced  by  HBV  [27,28]. Secondly,  protective
nti-HBs  titers  are  crucial  for  RT  candidates  to  be  included  in
he  waiting  list  from  donors  with  evidence  of  HBV  infection
hepatitis  B  surface  antigen-negative/anti-hepatitis  B  core-
ositive).  In  fact,  the  increasing  demand  for  available  organ
onors  for  RT  and  the  continuing  shortage  of  organs  has  led
any  transplant  centers  to  expand  their  acceptance  criteria
y  including  deceased  donors  with  special  clinical  situations
such  as  kidney  donors  with  evidence  of  HBV  infection)  [29].
t  last,  we  must  consider  that  many  of  the  patients  with
KD  in  the  pre-dialysis  phase  begin  long-term  haemodialy-
is;  there  is  the  opportunity  for  HBsAg  negative  patients  with
rotective  levels  of  anti-HBs  antibody  in  serum  to  undergo
D  even  in  shifts  and  machines  dedicated  to  HBsAg  posi-
ive  patients.  Isolation  of  HBsAg  positive  carriers  by  rooms,
achines,  and  staff  is  still  an  important  preventive  measure
gainst  the  spread  of  HBV  within  dialysis  units,  as  recom-
ended  by  the  CDC  [3].
We  believe  that  the  clinical  benefits  conferred  from  HBV
accine  need  to  be  obtained  in  susceptible  CKD  patients  as
oon  as  possible;  thus  we  have  adopted  an  accelerated  vac-
ine  schedule  (1,  2,  3,  and  4  months)  in  comparison  with  thetion  with  Fendrix  is  effective  and  safe  in  pre-dialysis  CKD
.org/10.1016/j.clinre.2019.06.010
he  manufacturers.  In  fact,  the  accelerated  vaccine  sched-
le  allows  the  achievement  of  protective  antibody  levels
ore  faster  than  the  standard  vaccine  schedule.
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Table  5  Available  data  on  the  use  of  Fendrix  in  patients  with  CKD.
Authors  Ref  Patients,  n  CKD  status,  n
Lindemann  M  et  al.,  2017  [17]  7/17  (41.2%)  RT
Fabrizi F  et  al.,  2015  [16]  76/91  (84%)  HD
Surquin M  et  al.,  2010 [14]  117/149  (78.6%) HD  (45%),  PD  (13.4%),  pre-dialysis  (41.6%)
Kong N  et  al.,  2005  [13]  74/82  (90.9%)  HD  (54%),  pre-dialysis  (46%)
ysis; 
[
[
[
[
[
[
[
[
[
[CKD: chronic kidney disease; RT: renal transplant; HD: haemodial
Conclusion
Our  prospective  cohort  study  conducted  in  a  ‘real-life’  set-
ting  suggests  a  great  immunogenicity  and  safety  of  HBV-AS04
among  patients  with  CKD  not  requiring  maintenance  dialysis.
Studies  are  under  way  to  assess  the  persistence  of  anti-HBs
antibodies  in  patients  with  CKD  who  have  been  subjected  to
active  immunization  successfully.
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